RBC maintains Outperform on Ariad

|By:, SA News Editor

RBC's Michael Yee maintains an Outperform rating on Ariad Pharmaceuticals (ARIA).

Yee is looking forward to Iclusig data to be presented at a meeting of the American Society of Hematology this December.

Price target is $28, representing a 25% upside from Friday's close.

See also: Iclusig TRx +5.4% w/w